Abstracts tagged "registry"

Abstract Number: 0282 • ACR Convergence 2024
Electronic Health Record-Based Calcium Pyrophosphate Deposition Disease Registry: A Feasibility Study
Nils Bürgisser¹, Denis Mongin², Samia Mehouachi², Delphine Sophie Courvoisier³ and Kim Lauper⁴, ¹Division of Rheumatology and internal medicine, Geneva University Hospital, Switzerland, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Despite its prevalence, calcium pyrophosphate deposition disease (CPPD) remains insufficiently studied. Leveraging electronic health record (EHR) data, a rich source of patient information, could…
Abstract Number: 1114 • ACR Convergence 2024
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
paula pérez garcía¹, Miriam Retuerto Guerrero², yanira chuquimia mendoza³, Jesús Loarce⁴, Belén Atienza-Mateo⁵, Carolina Merino⁶, marina pavia pascual⁷, cristiana sieiro santos⁸, Clara Moriano⁹ and elvira Diez álvarez¹⁰, ¹Complejo Asistencial Universitario de León, león, Spain, ²Complejo Asistencial Universitario de León, Leon, Spain, ³Complejo asistencial univeritario de león, león, Spain, ⁴Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ⁷Hospital General Universitario Gregorio Marañon, madrid, Spain, ⁸Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis…
Abstract Number: 2055 • ACR Convergence 2024
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
Laura Kopplin¹ and Karen Armbrust², ¹Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease. 30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
Abstract Number: 0345 • ACR Convergence 2024
Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry
Chester Oddis¹, Jan Feifel², Dana Ascherman³, Diane Carol Koontz⁴, Caroline Foch², Luisa Henkel⁵, Jeffrey M. Muir⁶, Deborah Denis⁷ and Rohit Aggarwal⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²the healthcare business of Merck KGaA, Darmstadt, Germany, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany, Weiterstadt, Germany, ⁶Cytel, Inc., Toronto, Canada, ⁷EMD Serono, Rockland, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Glucocorticoids (GC) in high doses remain the first-line treatment for dermatomyositis (DM). One or more immunosuppressive agents are given concomitantly as steroid-sparing agents to…
Abstract Number: 1168 • ACR Convergence 2024
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Masataka Kuwana¹, Kenichi Masui², Atsushi Kawakami³, Takafumi Suda⁴, Shinji Sato⁵, Yasushi Kawaguchi⁶, Takeshi Johkoh⁷, Tomoaki Hoshino⁸, Naoki Shimada⁹, Yasuhiro Kondoh¹⁰, Yoshinori Tanino¹¹, Tohru Takeuchi¹², Yoshiyuki Abe¹³, Naoki Kimura¹⁴, Yasushi Inoue¹⁵, Keisuke Tomii¹⁶, Toru Arai¹⁷, Kunihiro Yamaoka¹⁸, Kaneshige Sasaki¹⁹, Taio Naniwa²⁰, Ran Nakashima²¹, Kenjiro Shima²², Osamu Nishiyama²³, Yuko Waseda²⁴, Hiroshi Mukae²⁵, Hirofumi Chiba²⁶, Keigo Ikeda²⁷, Kazuya Ichikado²⁸, Yohei Kirino², Koichi Amano²⁹, Takashi Nawata³⁰, Tomoo Kishaba³¹, Daisuke Asatori³², Daisuke Kobayashi²² and Takahisa Gono³³, ¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ²Yokohama City University School of Medicine, Yokohama, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁵Tokai University School of Medicine, Isehara, Japan, ⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁷Kansai Rosai Hospital, Amagasaki, Japan, ⁸Kurume University School of Medicine, Kurume, Japan, ⁹International University of Health and Welfare, Ohtawara, Japan, ¹⁰Tosei General Hospital, Seto, Japan, ¹¹Fukushima Medical University School of Medicine, Fukushima, Japan, ¹²Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ¹⁶Kobe City Medical Center General Hospital, Kobe, Japan, ¹⁷NHO Kinki Chuo Chest Medical Center, Sakai, Japan, ¹⁸Kitasato University School of Medicine, Sagamihara, Japan, ¹⁹Kainan Hospital, Yatomi, Japan, ²⁰Nagoya City University, Nagoya, Japan, ²¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²²Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²³Kindai University Faculty of Medicine, Osakasayama, Japan, ²⁴University of Fukui, Eiheiji, Japan, ²⁵Nagasaki University Hospital, Nagasaki, Japan, ²⁶Sapporo Medical University, Sapporo, Japan, ²⁷Juntendo University Urayasu Hospital, Urayasu, Japan, ²⁸Saiseikai Kumamoto Hospital, Kumamoto, Japan, ²⁹Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan, ³⁰Yamaguchi University Graduate School of Medicine, Ube, Japan, ³¹Okinawa Chubu Hospital, Uruma, Japan, ³²Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ³³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…
Abstract Number: 2208 • ACR Convergence 2024
Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Aparna Swaminathan¹, Jeremy Weber², Jamie Todd³, Scott Palmer³, Megan Neely³, Peide Li⁴ and Ann Chauffe⁵, and on behalf of the ILD-PRO Registry investigators, ¹Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT
Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…
Abstract Number: 0378 • ACR Convergence 2024
Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Michelle Batthish⁷, Jon Burnham⁸, Danielle Fair⁹, Suhas Ganguli¹⁰, Mileka Gilbert¹¹, Beth Gottlieb¹², Tzielan Lee¹³, Daniel Lovell¹⁴, Melissa Mannion¹⁵, Edward Oberle¹⁶, Nancy Pan¹⁷, Linda Ray¹⁸, Michael Shishov¹⁹, Mary Toth²⁰ and Esi Morgan²¹, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷McMaster Children's Hospital, Hamilton, ON, Canada, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹⁰Hackensack University Medical Center, Hackensack, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵University of Alabama at Birmingham, Birmingham, AL, ¹⁶Nationwide Children's Hospital, Columbus, OH, ¹⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ¹⁸University of Mississippi Medical Center, Jackson, MS, ¹⁹Phoenix Children's Hospital, Phoenix, AZ, ²⁰Nemours Foundation, Orlando, FL, ²¹Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes in patients with juvenile…
Abstract Number: 1226 • ACR Convergence 2024
The Problem of Pain in Systemic Lupus Erythematosus: A Comprehensive Analysis of Pain Distribution Using the CHOIR Body Map and PROMIS Measures
Tiffany Jiang¹, Sean Mackey², Beth Darnall², Julia Simard³ and Titilola Falasinnu⁴, ¹Yale School of Medicine, New Haven, CT, ²Stanford School of Medicine, Stanford, ³Stanford School of Medicine, Stanford, CA, ⁴Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE), characterized by an autoimmune attack of healthy tissues, presents a complex collection of symptoms affecting multiple organ systems. Among these,…
Abstract Number: 2275 • ACR Convergence 2024
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Lucia Otero-Varela¹, Carlos Sanchez-Piedra², Elena Rabadán Rubio³, Juan Camilo Sarmiento-Monroy⁴, Chamaida Plasencia-Rodríguez⁵, Diana Sueiro⁶, Olga Martinez⁷, Noemí Busquets Pérez⁸, Mercedes Freire González⁹, Fernando Sánchez-Alonso¹⁰, José María Álvaro-Gracia¹¹ and Isabel Castrejon¹², and BIOBADASER group, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, ³Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁴Hospital Clínic Barcelona, Barcelona, Spain, ⁵Hospital Universitario La Paz, MADRID, Spain, ⁶Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁷Hospital Universitario de Salamanca, Zamora, Spain, ⁸HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁹Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Gregorio Marañón, Madrid, Spain, ¹²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients…
Abstract Number: 0447 • ACR Convergence 2024
Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Connie Lin¹, Anja Geldhof², Mauricio Ballina³, Hetal Patel⁴ and Hewei Li⁵, ¹Janssen R&D US, Horsham, PA, ²Director Postmarketing Commitments, Leiden, Netherlands, ³Actelion Research & Development, Basel, Switzerland, Gewerbestrasse, Basel-Landschaft, Switzerland, ⁴Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, ⁵Janssen Pharmaceutical, Hopewell Township, NJ
Background/Purpose: Data pertaining to the use of biologics in immunologic diseases are limited on their use during pregnancy. Guselkumab (GUS) is a human IgG1λ mAb…
Abstract Number: 1271 • ACR Convergence 2024
Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset
Jordan Roberts¹, Anna Faino², Min-Lee Chang³, Jonathan Cogen⁴, Matt Hall⁵ and Esi Morgan¹, and for the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ⁴Seattle Children’s Hospital, Seattle, WA, ⁵Children’s Hospital Association, Lenexa, KS
Background/Purpose: Currently, no comprehensive national multipayer dataset with inpatient and outpatient data exists for childhood rheumatologic diseases, limiting the ability to study outcomes longitudinally and…
Abstract Number: 2277 • ACR Convergence 2024
Switching to a Targeted Drug with a Different Mode of Action After Discontinuation of the First TNF Inhibitor Is Associated with Better Drug Survival Compared to a Second TNF Inhibitor in Rheumatoid Arthritis: A Propensity Score-matched Analysis from the Czech ATTRA Registry
Herman Mann¹, Jana Baranová², Pavel Horak³, Karel Pavelka⁴, Ladislav Šenolt⁵, Jiří Vencovský⁵, Kateřina Kusalová² and Jakub Závada⁴, and ATTRA registry, ¹Revmatologický ústav, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: TNF inhibitors (TNFi) are currently the most commonly used first-line targeted therapy for patients with rheumatoid arthritis (RA). After discontinuation of the first TNFi,…
Abstract Number: 0496 • ACR Convergence 2024
Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
Nils Steinz¹, Tjardo Maarseveen², Andrew Cope³, John Isaacs⁴, Aaron Winkler⁵, Thomas Huizinga⁶, Yann Abraham⁷ and Rachel Knevel¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, ³King's College London, London, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵Pfizer Inc., Cambridge, MA, ⁶Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁷Janssen Research and Development, Beerse, Belgium
Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…
Abstract Number: 1377 • ACR Convergence 2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Adrián Quevedo-Rodríguez¹, Lucia Otero-Varela², Fernando Sánchez-Alonso³, Yanira Pérez-Vera¹, Javier Manero-Ruiz⁴, Cristina Campos-Fernández⁵, Sara Manrique-Arija⁶, Paloma Vela-Casasempere⁷, Antonio Mera-Varela⁸, César Díaz⁹, Atusa Movasat¹⁰, Blanca Garcia-Magallon¹¹, Inmaculada Ros-Vilamajó¹², Carolina Perez-Garcia¹³ and Isabel Castrejon¹⁴, and BIOBADASER working group., ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Príncipe de Asturias, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ¹²Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain
Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
Abstract Number: 2283 • ACR Convergence 2024
Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
Joshua Baker¹, Kristi Mizelle², Wassim Saikali³, Page Moore⁴, Hyung-Joo Kang⁴, David Gruben⁵, Ahmed Shelbaya⁶, Lori Stockert⁷ and Jacqueline O'Brien⁴, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²TPMG Rheumatology, Newport News, VA, ³Rheumatology and Pulmonary Clinic, Beckley, WV, ⁴CorEvitas, LLC, Waltham, MA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Janus kinase inhibitors (JAKi) are a widely acceptable drug class in the treatment of RA. However, real-world data on the patterns of JAKi use and…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].